Trial 3G-16-4


A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Syma Iqbal, M.D.
Other Trial Staff:  Yan Ning, D.M., Charlean Ketchens, Coordinator, Raluca Agafitei, Coordinator, Yanli Wang, D.M., Rabia Rehman, Coordinator, Diana Oganyesyan, Coordinator, Janelle Luevano, Coordinator, Ramy Farag, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.